Clinical Trial Update: Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

An exploratory Phase 2 study evaluating SHR-0302 and SHR-2554 in patients with relapsed or refractory peripheral T-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• SHR-0302
• SHR-2554

Snippet

Sponsor: Fudan University | Conditions: Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | Status: RECRUITING